Leadiant loses Dutch excessive-pricing appeal, wins review of collusion complaint
Drugmaker Leadiant Biosciences has lost its appeal against a 17 million-euro fine that the Dutch competition authority imposed on it for abusing a dominant position in a landmark case on excessive...To view the full article, register now.
Already a subscriber? Click here to view full article